Date 05/06/2011

To Jim Henry, Ray Henry, Kathy Kerr, Jim Schwartz

From Rob Bacon, Maaike Bose, Rob Hinkle, Debbie Reichart, Haruko Mizoguchi

Subject Topline Results from CRB 11-01-004 (SSS 19) Treatment Phase

Objective

To build our understanding of the best time-points (early or regression) and which biomarkers best enable the testing of new excipients in the presence of ZPT in the Split Scalp Tonic model.

Treatment Comparisons

1. 0.03% ZPT tonic compared to 0.10% ZPT tonic
2. 0.03% ZPT tonic compared to 0.03% ZPT + 0.06% Zinc Carbonate (ZC) tonic

This document contains the ASFS, IMAC, Histamine, Cytokine, and SkinMap data for the treatment phase portion of SSS 19.

The biomarker samples from the regression phase have not undergone Analytical assay at this time.

Success Criteria

To show a statistically significant reduction in ASFS and biomarkers for 0.03% ZPT tonic compared to 0.10% ZPT tonic and a reduction in ASFS and biomarkers for 0.03% ZPT tonic compared to 0.03% ZPT + ZC tonic.

Treatments were considered statistically significantly different if pairwise p-value (two-sided) ≤ 0.20.

Results

ASFS

* All treatments produced progressively greater flaking reduction from baseline over 3-week treatment period with post-treatment time points of Week 1, 2 and 3.
* No significant differences between 0.10% ZPT tonic and 0.03% ZPT tonic were detected at all of the time points.
* No significant differences between 0.03% ZPT + ZC tonic and 0.03% ZPT tonic were detected at all of the time points.

IMAC

* Scalp swab samples were collected at Baseline, Week 3, and Regression Week 3. A subset of scalp swab samples was analyzed for the Baseline and Week 3 time points. Samples collected at the Regression Week 3 were not analyzed.
* The 0.10% ZPT tonic reduced *Malassezia* by 96.7% which was statistically significantly different from the 92.6% reduction with 0.03% ZPT tonic (p-value=0.0001) following 3 weeks of treatment.
* The 0.03% ZPT + ZC tonic reduced *Malassezia* by 91.2% compared to 88.5% reduction with 0.03% ZPT tonic (p-value=0.1396) following three weeks of treatment.

Biomarkers

* The 0.10% ZPT tonic produced a significantly greater reduction in protein normalized Histamine compared to 0.03% ZPT tonic at Week 1 and 3 (-33% vs. -12% with p-values=0.0722 at Week 1 and -47% vs. -31% with p-value=0.1173 at Week 3).
* See Table 1 for an overview of biomarker results.

|  |  |
| --- | --- |
|  |  |
|  |  |

|  |  |
| --- | --- |
|  |  |
|  |  |

**Table 1**



***CRB 11-01-004 SSS 19***

***Asfs Analysis***

| **Treatment Pair** | **Week 1 Adjusted Mean Difference** | **Std Err** | **P-Value (Two-Sided)** | **Lower 90% Confidence Bound** | **Upper 90% Confidence Bound** |
| --- | --- | --- | --- | --- | --- |
| [A] 0.03% ZPT-[B] 0.10% ZPT | 0.011 | 0.2410 | 0.9639 | -0.390 | 0.412 |
| [C] 0.03% ZPT-[D] 0.03% ZPT + 0.06% ZC | -0.181 | 0.2601 | 0.4887 | -0.614 | 0.252 |

***CRB 11-01-004 SSS 19***

***Asfs Analysis***

| **Visit** | **Treatment** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Standard Error** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 14.767 | 0.000 | 0.3089 | 0.6745 |
|  | [B] 0.10% ZPT | 86 | 14.884 | 0.000 | 0.3089 | . |
| Week 1 | [A] 0.03% ZPT | 83 | 13.367 | -1.428 | 0.3227 | 0.9639 |
|  | [B] 0.10% ZPT | 83 | 13.356 | -1.439 | 0.3227 | . |
|  | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 15.354 | 0.000 | 0.3871 | 0.9008 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 15.390 | 0.000 | 0.3871 | . |
| Week 1 | [C] 0.03% ZPT | 86 | 13.479 | -1.893 | 0.3091 | 0.4887 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 13.660 | -1.712 | 0.3091 | . |
|  | | | | | | |

***CRB 11-01-004 SSS 19***

***ASFS Analysis***

| **Treatment Pair** | **Week 2 Adjusted Mean Difference** | **Std Err** | **P-Value (Two-Sided)** | **Lower 90% Confidence Bound** | **Upper 90% Confidence Bound** |
| --- | --- | --- | --- | --- | --- |
| [A] 0.03% ZPT-[B] 0.10% ZPT | -0.026 | 0.2673 | 0.9238 | -0.470 | 0.419 |
| [C] 0.03% ZPT-[D] 0.03% ZPT + 0.06% ZC | -0.216 | 0.2938 | 0.4653 | -0.704 | 0.273 |

***CRB 11-01-004 SSS 19***

***ASFS Analysis***

| **Visit** | **Treatment** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Standard Error** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 14.767 | 0.000 | 0.3089 | 0.6745 |
|  | [B] 0.10% ZPT | 86 | 14.884 | 0.000 | 0.3089 | . |
| Week 2 | [A] 0.03% ZPT | 85 | 11.517 | -3.307 | 0.4348 | 0.9238 |
|  | [B] 0.10% ZPT | 85 | 11.542 | -3.281 | 0.4348 | . |
|  | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 15.354 | 0.000 | 0.3871 | 0.9008 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 15.390 | 0.000 | 0.3871 | . |
| Week 2 | [C] 0.03% ZPT | 84 | 11.737 | -3.667 | 0.4222 | 0.4653 |
|  | [D] 0.03% ZPT + 0.06% ZC | 84 | 11.953 | -3.452 | 0.4222 | . |
|  | | | | | | |

***CRB 11-01-004 SSS 19***

***Asfs Analysis***

| **Treatment Pair** | **Week 3 Adjusted Mean Difference** | **Std Err** | **P-Value (Two-Sided)** | **Lower 90% Confidence Bound** | **Upper 90% Confidence Bound** |
| --- | --- | --- | --- | --- | --- |
| [A] 0.03% ZPT-[B] 0.10% ZPT | 0.277 | 0.3413 | 0.4195 | -0.291 | 0.845 |
| [C] 0.03% ZPT-[D] 0.03% ZPT + 0.06% ZC | -0.109 | 0.3228 | 0.7366 | -0.646 | 0.428 |

***CRB 11-01-004 SSS 19***

***Asfs Analysis***

| **Visit** | **Treatment** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Standard Error** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 14.767 | 0.000 | 0.3089 | 0.6745 |
|  | [B] 0.10% ZPT | 86 | 14.884 | 0.000 | 0.3089 | . |
| Week 3 | [A] 0.03% ZPT | 85 | 9.491 | -5.344 | 0.4924 | 0.4195 |
|  | [B] 0.10% ZPT | 85 | 9.214 | -5.621 | 0.4924 | . |
|  | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 15.354 | 0.000 | 0.3871 | 0.9008 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 15.390 | 0.000 | 0.3871 | . |
| Week 3 | [C] 0.03% ZPT | 83 | 10.235 | -5.175 | 0.4539 | 0.7366 |
|  | [D] 0.03% ZPT + 0.06% ZC | 83 | 10.344 | -5.066 | 0.4539 | . |
|  | | | | | | |

***CRB 11-01-004 SSS 19***

***Analysis for Log Histamine Normalized***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | -0.574 | 0.000 | . | 0.1057 | 0.27 | 0.00 | 0.00 | 0.00 | 0.9208 |
|  | [B] 0.10% ZPT | 86 | -0.580 | 0.000 | . | 0.1057 | 0.26 | 0.00 | 0.00 | 0.00 | . |
| Week 1 | [A] 0.03% ZPT | 85 | -0.640 | -0.055 | 0.3571 | 0.0595 | 0.23 | -11.9 | -23.2 | 1.02 | 0.0722 |
|  | [B] 0.10% ZPT | 85 | -0.762 | -0.177 | 0.0039 | 0.0595 | 0.17 | -33.4 | -42.0 | -23.7 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | -0.598 | 0.000 | . | 0.1064 | 0.25 | 0.00 | 0.00 | 0.00 | 0.2364 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | -0.688 | 0.000 | . | 0.1064 | 0.21 | 0.00 | 0.00 | 0.00 | . |
| Week 1 | [C] 0.03% ZPT | 86 | -0.853 | -0.210 | 0.0009 | 0.0612 | 0.14 | -38.3 | -46.4 | -29.0 | 0.0600 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | -0.713 | -0.071 | 0.2507 | 0.0612 | 0.19 | -15.0 | -26.2 | -2.18 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19***

***Analysis for Log IL1raIL1a Ratio***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 0.214 | 0.000 | . | 0.0681 | 1.64 | 0.00 | 0.00 | 0.00 | 0.7802 |
|  | [B] 0.10% ZPT | 86 | 0.202 | 0.000 | . | 0.0681 | 1.59 | 0.00 | 0.00 | 0.00 | . |
| Week 1 | [A] 0.03% ZPT | 84 | 0.142 | -0.060 | 0.0635 | 0.0320 | 1.39 | -12.9 | -19.1 | -6.28 | 0.1793 |
|  | [B] 0.10% ZPT | 85 | 0.203 | 0.001 | 0.9768 | 0.0318 | 1.60 | 0.21 | -6.86 | 7.82 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 0.200 | 0.000 | . | 0.0791 | 1.58 | 0.00 | 0.00 | 0.00 | 0.3189 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.246 | 0.000 | . | 0.0791 | 1.76 | 0.00 | 0.00 | 0.00 | . |
| Week 1 | [C] 0.03% ZPT | 86 | 0.176 | -0.047 | 0.2273 | 0.0384 | 1.50 | -10.2 | -17.8 | -1.89 | 0.2304 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.118 | -0.105 | 0.0075 | 0.0384 | 1.31 | -21.5 | -28.1 | -14.3 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19***

***Analysis for Log IL1ra Normalized***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 1.113 | 0.000 | . | 0.0434 | 12.98 | 0.00 | 0.00 | 0.00 | 0.5562 |
|  | [B] 0.10% ZPT | 86 | 1.094 | 0.000 | . | 0.0434 | 12.42 | 0.00 | 0.00 | 0.00 | . |
| Week 1 | [A] 0.03% ZPT | 84 | 1.084 | -0.020 | 0.5005 | 0.0301 | 12.13 | -4.57 | -11.0 | 2.26 | 0.5307 |
|  | [B] 0.10% ZPT | 85 | 1.109 | 0.004 | 0.8820 | 0.0299 | 12.84 | 1.03 | -5.69 | 8.23 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 1.084 | 0.000 | . | 0.0444 | 12.14 | 0.00 | 0.00 | 0.00 | 0.2957 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.118 | 0.000 | . | 0.0444 | 13.12 | 0.00 | 0.00 | 0.00 | . |
| Week 1 | [C] 0.03% ZPT | 86 | 1.080 | -0.021 | 0.5088 | 0.0317 | 12.02 | -4.72 | -11.4 | 2.48 | 0.3424 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.043 | -0.058 | 0.0707 | 0.0317 | 11.04 | -12.5 | -18.7 | -5.88 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19***

***Analysis for Log IL1a Normalized***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 0.900 | 0.000 | . | 0.0373 | 7.94 | 0.00 | 0.00 | 0.00 | 0.7491 |
|  | [B] 0.10% ZPT | 86 | 0.892 | 0.000 | . | 0.0373 | 7.81 | 0.00 | 0.00 | 0.00 | . |
| Week 1 | [A] 0.03% ZPT | 84 | 0.941 | 0.039 | 0.0605 | 0.0206 | 8.74 | 9.46 | 4.38 | 14.78 | 0.2282 |
|  | [B] 0.10% ZPT | 85 | 0.906 | 0.004 | 0.8480 | 0.0205 | 8.05 | 0.91 | -3.74 | 5.79 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 0.884 | 0.000 | . | 0.0463 | 7.66 | 0.00 | 0.00 | 0.00 | 0.6611 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.872 | 0.000 | . | 0.0463 | 7.45 | 0.00 | 0.00 | 0.00 | . |
| Week 1 | [C] 0.03% ZPT | 86 | 0.906 | 0.028 | 0.2221 | 0.0227 | 8.06 | 6.66 | 1.21 | 12.39 | 0.5316 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.923 | 0.045 | 0.0519 | 0.0227 | 8.38 | 10.88 | 5.22 | 16.84 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19***

***Analysis for Log Protein Histamine***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 1.308 | 0.000 | . | 0.0238 | 20.31 | 0.00 | 0.00 | 0.00 | 0.7864 |
|  | [B] 0.10% ZPT | 86 | 1.314 | 0.000 | . | 0.0238 | 20.62 | 0.00 | 0.00 | 0.00 | . |
| Week 1 | [A] 0.03% ZPT | 85 | 1.254 | -0.055 | 0.0114 | 0.0211 | 17.96 | -11.8 | -16.0 | -7.42 | 0.2118 |
|  | [B] 0.10% ZPT | 85 | 1.278 | -0.031 | 0.1516 | 0.0211 | 18.98 | -6.79 | -11.2 | -2.15 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 1.321 | 0.000 | . | 0.0264 | 20.96 | 0.00 | 0.00 | 0.00 | 0.3804 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.342 | 0.000 | . | 0.0264 | 21.97 | 0.00 | 0.00 | 0.00 | . |
| Week 1 | [C] 0.03% ZPT | 86 | 1.264 | -0.067 | 0.0038 | 0.0226 | 18.38 | -14.4 | -18.7 | -9.79 | 0.3394 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.242 | -0.089 | 0.0002 | 0.0226 | 17.48 | -18.6 | -22.7 | -14.2 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19***

***Analysis for Log Protein Cytokine***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 0.988 | 0.000 | . | 0.0294 | 9.72 | 0.00 | 0.00 | 0.00 | 0.9484 |
|  | [B] 0.10% ZPT | 86 | 0.986 | 0.000 | . | 0.0294 | 9.68 | 0.00 | 0.00 | 0.00 | . |
| Week 1 | [A] 0.03% ZPT | 84 | 0.859 | -0.124 | <.0001 | 0.0248 | 7.22 | -24.8 | -29.0 | -20.4 | 0.6967 |
|  | [B] 0.10% ZPT | 85 | 0.869 | -0.113 | <.0001 | 0.0247 | 7.40 | -22.9 | -27.2 | -18.4 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 0.953 | 0.000 | . | 0.0354 | 8.97 | 0.00 | 0.00 | 0.00 | 0.4492 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.974 | 0.000 | . | 0.0354 | 9.42 | 0.00 | 0.00 | 0.00 | . |
| Week 1 | [C] 0.03% ZPT | 86 | 0.873 | -0.090 | 0.0008 | 0.0259 | 7.47 | -18.8 | -23.5 | -13.8 | 0.7438 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.864 | -0.099 | 0.0003 | 0.0259 | 7.32 | -20.4 | -25.0 | -15.5 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19***

***Analysis for Log Histamine***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 0.734 | 0.000 | . | 0.1099 | 5.42 | 0.00 | 0.00 | 0.00 | 0.9990 |
|  | [B] 0.10% ZPT | 86 | 0.734 | 0.000 | . | 0.1099 | 5.42 | 0.00 | 0.00 | 0.00 | . |
| Week 1 | [A] 0.03% ZPT | 85 | 0.616 | -0.108 | 0.1047 | 0.0658 | 4.13 | -22.0 | -33.0 | -9.25 | 0.1471 |
|  | [B] 0.10% ZPT | 85 | 0.515 | -0.209 | 0.0021 | 0.0658 | 3.27 | -38.2 | -46.9 | -28.1 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 0.724 | 0.000 | . | 0.1120 | 5.29 | 0.00 | 0.00 | 0.00 | 0.3727 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.654 | 0.000 | . | 0.1120 | 4.51 | 0.00 | 0.00 | 0.00 | . |
| Week 1 | [C] 0.03% ZPT | 86 | 0.417 | -0.272 | 0.0002 | 0.0699 | 2.61 | -46.5 | -54.5 | -37.2 | 0.1512 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.523 | -0.166 | 0.0202 | 0.0699 | 3.34 | -31.7 | -41.9 | -19.8 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19***

***Analysis for Log IL1ra***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 2.101 | 0.000 | . | 0.0591 | 126.17 | 0.00 | 0.00 | 0.00 | 0.6488 |
|  | [B] 0.10% ZPT | 86 | 2.080 | 0.000 | . | 0.0591 | 120.20 | 0.00 | 0.00 | 0.00 | . |
| Week 1 | [A] 0.03% ZPT | 84 | 1.944 | -0.143 | 0.0010 | 0.0418 | 87.81 | -28.1 | -34.7 | -20.8 | 0.4677 |
|  | [B] 0.10% ZPT | 85 | 1.977 | -0.109 | 0.0101 | 0.0416 | 94.86 | -22.3 | -29.4 | -14.5 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 2.037 | 0.000 | . | 0.0654 | 108.89 | 0.00 | 0.00 | 0.00 | 0.2398 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 2.092 | 0.000 | . | 0.0654 | 123.56 | 0.00 | 0.00 | 0.00 | . |
| Week 1 | [C] 0.03% ZPT | 86 | 1.952 | -0.112 | 0.0269 | 0.0498 | 89.59 | -22.8 | -31.1 | -13.4 | 0.4267 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.908 | -0.156 | 0.0024 | 0.0498 | 80.94 | -30.2 | -37.8 | -21.7 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19***

***Analysis for Log IL1a***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 1.887 | 0.000 | . | 0.0398 | 77.16 | 0.00 | 0.00 | 0.00 | 0.7154 |
|  | [B] 0.10% ZPT | 86 | 1.878 | 0.000 | . | 0.0398 | 75.55 | 0.00 | 0.00 | 0.00 | . |
| Week 1 | [A] 0.03% ZPT | 84 | 1.799 | -0.085 | 0.0079 | 0.0312 | 63.02 | -17.8 | -23.5 | -11.6 | 0.4216 |
|  | [B] 0.10% ZPT | 85 | 1.775 | -0.109 | 0.0007 | 0.0311 | 59.58 | -22.3 | -27.6 | -16.5 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 1.837 | 0.000 | . | 0.0498 | 68.73 | 0.00 | 0.00 | 0.00 | 0.7537 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.846 | 0.000 | . | 0.0498 | 70.19 | 0.00 | 0.00 | 0.00 | . |
| Week 1 | [C] 0.03% ZPT | 86 | 1.783 | -0.059 | 0.1004 | 0.0355 | 60.63 | -12.7 | -19.6 | -5.27 | 0.9658 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.784 | -0.058 | 0.1092 | 0.0355 | 60.83 | -12.4 | -19.3 | -4.94 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19***

***Analysis for Log Hsa Normalized***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 0.754 | 0.000 | . | 0.0768 | 5.67 | 0.00 | 0.00 | 0.00 | 0.6871 |
|  | [B] 0.10% ZPT | 86 | 0.733 | 0.000 | . | 0.0768 | 5.41 | 0.00 | 0.00 | 0.00 | . |
| Week 1 | [A] 0.03% ZPT | 85 | 0.369 | -0.362 | <.0001 | 0.0569 | 2.34 | -56.5 | -61.8 | -50.4 | 0.5616 |
|  | [B] 0.10% ZPT | 85 | 0.335 | -0.396 | <.0001 | 0.0569 | 2.16 | -59.8 | -64.7 | -54.2 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 0.738 | 0.000 | . | 0.0683 | 5.47 | 0.00 | 0.00 | 0.00 | 0.4100 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.695 | 0.000 | . | 0.0683 | 4.96 | 0.00 | 0.00 | 0.00 | . |
| Week 1 | [C] 0.03% ZPT | 86 | 0.499 | -0.217 | 0.0001 | 0.0541 | 3.16 | -39.4 | -46.5 | -31.3 | 0.1576 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.588 | -0.128 | 0.0204 | 0.0541 | 3.88 | -25.5 | -34.3 | -15.6 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19***

***Analysis for Log Involucrin Normalized***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | -1.585 | 0.000 | . | 0.0370 | 0.03 | 0.00 | 0.00 | 0.00 | 0.1971 |
|  | [B] 0.10% ZPT | 86 | -1.540 | 0.000 | . | 0.0370 | 0.03 | 0.00 | 0.00 | 0.00 | . |
| Week 1 | [A] 0.03% ZPT | 85 | -1.524 | 0.038 | 0.2727 | 0.0340 | 0.03 | 9.02 | 0.82 | 17.89 | 0.6263 |
|  | [B] 0.10% ZPT | 85 | -1.547 | 0.014 | 0.6811 | 0.0340 | 0.03 | 3.28 | -4.49 | 11.68 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | -1.513 | 0.000 | . | 0.0427 | 0.03 | 0.00 | 0.00 | 0.00 | 0.2712 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | -1.555 | 0.000 | . | 0.0427 | 0.03 | 0.00 | 0.00 | 0.00 | . |
| Week 1 | [C] 0.03% ZPT | 86 | -1.508 | 0.026 | 0.4627 | 0.0346 | 0.03 | 6.05 | -2.07 | 14.84 | 0.8883 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | -1.514 | 0.020 | 0.5592 | 0.0346 | 0.03 | 4.78 | -3.24 | 13.46 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19***

***Analysis for Log Keratins11011 Normalized***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 0.722 | 0.000 | . | 0.0712 | 5.27 | 0.00 | 0.00 | 0.00 | 0.8236 |
|  | [B] 0.10% ZPT | 86 | 0.708 | 0.000 | . | 0.0712 | 5.11 | 0.00 | 0.00 | 0.00 | . |
| Week 1 | [A] 0.03% ZPT | 85 | 0.875 | 0.144 | 0.0005 | 0.0401 | 7.50 | 39.40 | 27.12 | 52.86 | 0.9872 |
|  | [B] 0.10% ZPT | 85 | 0.874 | 0.143 | 0.0006 | 0.0401 | 7.49 | 39.15 | 26.90 | 52.60 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 0.768 | 0.000 | . | 0.0594 | 5.86 | 0.00 | 0.00 | 0.00 | 0.5861 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.736 | 0.000 | . | 0.0594 | 5.44 | 0.00 | 0.00 | 0.00 | . |
| Week 1 | [C] 0.03% ZPT | 86 | 0.832 | 0.080 | 0.0720 | 0.0438 | 6.79 | 20.18 | 8.65 | 32.94 | 0.7456 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.849 | 0.098 | 0.0286 | 0.0438 | 7.07 | 25.20 | 13.19 | 38.49 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19***

***Analysis for Log Protein SkinMap***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 1.148 | 0.000 | . | 0.0340 | 14.07 | 0.00 | 0.00 | 0.00 | 0.7299 |
|  | [B] 0.10% ZPT | 86 | 1.138 | 0.000 | . | 0.0340 | 13.73 | 0.00 | 0.00 | 0.00 | . |
| Week 1 | [A] 0.03% ZPT | 85 | 0.999 | -0.140 | <.0001 | 0.0331 | 9.99 | -27.6 | -32.9 | -21.9 | 0.7416 |
|  | [B] 0.10% ZPT | 85 | 0.988 | -0.152 | <.0001 | 0.0331 | 9.72 | -29.5 | -34.7 | -23.9 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 1.127 | 0.000 | . | 0.0381 | 13.41 | 0.00 | 0.00 | 0.00 | 0.7466 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.118 | 0.000 | . | 0.0381 | 13.11 | 0.00 | 0.00 | 0.00 | . |
| Week 1 | [C] 0.03% ZPT | 86 | 1.039 | -0.084 | 0.0200 | 0.0353 | 10.93 | -17.5 | -24.0 | -10.6 | 0.4094 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.008 | -0.115 | 0.0017 | 0.0353 | 10.18 | -23.2 | -29.2 | -16.7 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19***

***Analysis for Log Hsa***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 1.902 | 0.000 | . | 0.0887 | 79.79 | 0.00 | 0.00 | 0.00 | 0.6195 |
|  | [B] 0.10% ZPT | 86 | 1.871 | 0.000 | . | 0.0887 | 74.25 | 0.00 | 0.00 | 0.00 | . |
| Week 1 | [A] 0.03% ZPT | 85 | 1.369 | -0.501 | <.0001 | 0.0602 | 23.39 | -68.5 | -72.6 | -63.8 | 0.4587 |
|  | [B] 0.10% ZPT | 85 | 1.322 | -0.548 | <.0001 | 0.0602 | 20.99 | -71.7 | -75.4 | -67.5 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 1.865 | 0.000 | . | 0.0862 | 73.29 | 0.00 | 0.00 | 0.00 | 0.3990 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.813 | 0.000 | . | 0.0862 | 64.97 | 0.00 | 0.00 | 0.00 | . |
| Week 1 | [C] 0.03% ZPT | 86 | 1.537 | -0.302 | <.0001 | 0.0712 | 34.43 | -50.1 | -57.7 | -41.2 | 0.4232 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.597 | -0.242 | 0.0011 | 0.0712 | 39.55 | -42.7 | -51.4 | -32.5 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19***

***Analysis for Log Involucrin***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | -0.437 | 0.000 | . | 0.0526 | 0.37 | 0.00 | 0.00 | 0.00 | 0.5035 |
|  | [B] 0.10% ZPT | 86 | -0.402 | 0.000 | . | 0.0526 | 0.40 | 0.00 | 0.00 | 0.00 | . |
| Week 1 | [A] 0.03% ZPT | 85 | -0.528 | -0.107 | 0.0112 | 0.0411 | 0.30 | -21.8 | -28.8 | -14.0 | 0.5864 |
|  | [B] 0.10% ZPT | 85 | -0.556 | -0.134 | 0.0016 | 0.0411 | 0.28 | -26.6 | -33.2 | -19.3 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | -0.386 | 0.000 | . | 0.0556 | 0.41 | 0.00 | 0.00 | 0.00 | 0.2586 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | -0.437 | 0.000 | . | 0.0556 | 0.37 | 0.00 | 0.00 | 0.00 | . |
| Week 1 | [C] 0.03% ZPT | 86 | -0.470 | -0.058 | 0.2083 | 0.0459 | 0.34 | -12.5 | -21.3 | -2.79 | 0.4837 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | -0.506 | -0.094 | 0.0431 | 0.0459 | 0.31 | -19.5 | -27.6 | -10.5 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19***

***Analysis for Log Keratins11011***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 1.870 | 0.000 | . | 0.0590 | 74.18 | 0.00 | 0.00 | 0.00 | 0.6185 |
|  | [B] 0.10% ZPT | 86 | 1.846 | 0.000 | . | 0.0590 | 70.17 | 0.00 | 0.00 | 0.00 | . |
| Week 1 | [A] 0.03% ZPT | 85 | 1.874 | 0.003 | 0.9165 | 0.0321 | 74.83 | 0.78 | -6.41 | 8.52 | 0.7333 |
|  | [B] 0.10% ZPT | 85 | 1.863 | -0.008 | 0.8047 | 0.0321 | 72.90 | -1.82 | -8.82 | 5.72 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 1.895 | 0.000 | . | 0.0504 | 78.53 | 0.00 | 0.00 | 0.00 | 0.3748 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.854 | 0.000 | . | 0.0504 | 71.38 | 0.00 | 0.00 | 0.00 | . |
| Week 1 | [C] 0.03% ZPT | 86 | 1.868 | -0.006 | 0.8680 | 0.0355 | 73.86 | -1.35 | -9.10 | 7.05 | 0.8547 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.859 | -0.015 | 0.6766 | 0.0355 | 72.35 | -3.36 | -10.9 | 4.87 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Histamine Normalized***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | -0.574 | 0.000 | . | 0.1057 | 0.27 | 0.00 | 0.00 | 0.00 | 0.9208 |
|  | [B] 0.10% ZPT | 86 | -0.580 | 0.000 | . | 0.1057 | 0.26 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [A] 0.03% ZPT | 85 | -0.672 | -0.097 | 0.1611 | 0.0686 | 0.21 | -20.0 | -31.7 | -6.34 | 0.2477 |
|  | [B] 0.10% ZPT | 85 | -0.744 | -0.169 | 0.0159 | 0.0686 | 0.18 | -32.2 | -42.1 | -20.6 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | -0.598 | 0.000 | . | 0.1064 | 0.25 | 0.00 | 0.00 | 0.00 | 0.2364 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | -0.688 | 0.000 | . | 0.1064 | 0.21 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [C] 0.03% ZPT | 84 | -0.824 | -0.192 | 0.0113 | 0.0739 | 0.15 | -35.7 | -45.7 | -23.7 | 0.8043 |
|  | [D] 0.03% ZPT + 0.06% ZC | 84 | -0.843 | -0.211 | 0.0055 | 0.0739 | 0.14 | -38.5 | -48.1 | -27.0 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log IL1raIL1a Ratio***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 0.214 | 0.000 | . | 0.0681 | 1.64 | 0.00 | 0.00 | 0.00 | 0.7802 |
|  | [B] 0.10% ZPT | 86 | 0.202 | 0.000 | . | 0.0681 | 1.59 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [A] 0.03% ZPT | 85 | -0.010 | -0.228 | <.0001 | 0.0338 | 0.98 | -40.9 | -45.3 | -36.1 | 0.2490 |
|  | [B] 0.10% ZPT | 85 | 0.039 | -0.179 | <.0001 | 0.0338 | 1.09 | -33.8 | -38.8 | -28.4 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 0.200 | 0.000 | . | 0.0791 | 1.58 | 0.00 | 0.00 | 0.00 | 0.3189 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.246 | 0.000 | . | 0.0791 | 1.76 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [C] 0.03% ZPT | 84 | 0.055 | -0.149 | 0.0005 | 0.0408 | 1.13 | -29.0 | -35.3 | -22.0 | 0.3141 |
|  | [D] 0.03% ZPT + 0.06% ZC | 84 | 0.001 | -0.202 | <.0001 | 0.0408 | 1.00 | -37.3 | -42.9 | -31.1 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log IL1ra Normalized***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 1.113 | 0.000 | . | 0.0434 | 12.98 | 0.00 | 0.00 | 0.00 | 0.5562 |
|  | [B] 0.10% ZPT | 86 | 1.094 | 0.000 | . | 0.0434 | 12.42 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [A] 0.03% ZPT | 85 | 0.879 | -0.228 | <.0001 | 0.0332 | 7.56 | -40.8 | -45.2 | -36.1 | 0.3997 |
|  | [B] 0.10% ZPT | 85 | 0.912 | -0.194 | <.0001 | 0.0332 | 8.17 | -36.1 | -40.8 | -31.0 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 1.084 | 0.000 | . | 0.0444 | 12.14 | 0.00 | 0.00 | 0.00 | 0.2957 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.118 | 0.000 | . | 0.0444 | 13.12 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [C] 0.03% ZPT | 84 | 0.929 | -0.161 | <.0001 | 0.0356 | 8.49 | -31.0 | -36.5 | -25.2 | 0.2985 |
|  | [D] 0.03% ZPT + 0.06% ZC | 84 | 0.885 | -0.205 | <.0001 | 0.0356 | 7.67 | -37.6 | -42.5 | -32.3 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log IL1a Normalized***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 0.900 | 0.000 | . | 0.0373 | 7.94 | 0.00 | 0.00 | 0.00 | 0.7491 |
|  | [B] 0.10% ZPT | 86 | 0.892 | 0.000 | . | 0.0373 | 7.81 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [A] 0.03% ZPT | 85 | 0.888 | 0.000 | 0.9924 | 0.0215 | 7.73 | 0.05 | -4.78 | 5.12 | 0.5917 |
|  | [B] 0.10% ZPT | 85 | 0.873 | -0.015 | 0.4785 | 0.0215 | 7.46 | -3.46 | -8.12 | 1.43 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 0.884 | 0.000 | . | 0.0463 | 7.66 | 0.00 | 0.00 | 0.00 | 0.6611 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.872 | 0.000 | . | 0.0463 | 7.45 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [C] 0.03% ZPT | 84 | 0.878 | -0.009 | 0.7222 | 0.0247 | 7.55 | -2.01 | -7.43 | 3.73 | 0.9408 |
|  | [D] 0.03% ZPT + 0.06% ZC | 84 | 0.880 | -0.007 | 0.7895 | 0.0247 | 7.58 | -1.51 | -6.96 | 4.26 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Protein Histamine***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 1.308 | 0.000 | . | 0.0238 | 20.31 | 0.00 | 0.00 | 0.00 | 0.7864 |
|  | [B] 0.10% ZPT | 86 | 1.314 | 0.000 | . | 0.0238 | 20.62 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [A] 0.03% ZPT | 85 | 1.152 | -0.162 | <.0001 | 0.0206 | 14.18 | -31.1 | -34.3 | -27.8 | 0.7426 |
|  | [B] 0.10% ZPT | 85 | 1.159 | -0.155 | <.0001 | 0.0206 | 14.41 | -30.1 | -33.3 | -26.6 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 1.321 | 0.000 | . | 0.0264 | 20.96 | 0.00 | 0.00 | 0.00 | 0.3804 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.342 | 0.000 | . | 0.0264 | 21.97 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [C] 0.03% ZPT | 84 | 1.174 | -0.155 | <.0001 | 0.0225 | 14.94 | -30.0 | -33.5 | -26.2 | 0.6793 |
|  | [D] 0.03% ZPT + 0.06% ZC | 84 | 1.164 | -0.165 | <.0001 | 0.0225 | 14.60 | -31.5 | -35.0 | -27.9 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Protein Cytokine***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 0.988 | 0.000 | . | 0.0294 | 9.72 | 0.00 | 0.00 | 0.00 | 0.9484 |
|  | [B] 0.10% ZPT | 86 | 0.986 | 0.000 | . | 0.0294 | 9.68 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [A] 0.03% ZPT | 85 | 0.731 | -0.259 | <.0001 | 0.0262 | 5.38 | -44.9 | -48.2 | -41.5 | 0.0481 |
|  | [B] 0.10% ZPT | 85 | 0.782 | -0.208 | <.0001 | 0.0262 | 6.05 | -38.0 | -41.6 | -34.2 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 0.953 | 0.000 | . | 0.0354 | 8.97 | 0.00 | 0.00 | 0.00 | 0.4492 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.974 | 0.000 | . | 0.0354 | 9.42 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [C] 0.03% ZPT | 84 | 0.775 | -0.185 | <.0001 | 0.0272 | 5.96 | -34.7 | -38.7 | -30.5 | 0.2202 |
|  | [D] 0.03% ZPT + 0.06% ZC | 84 | 0.739 | -0.221 | <.0001 | 0.0272 | 5.48 | -39.9 | -43.6 | -36.0 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Histamine***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 0.734 | 0.000 | . | 0.1099 | 5.42 | 0.00 | 0.00 | 0.00 | 0.9990 |
|  | [B] 0.10% ZPT | 86 | 0.734 | 0.000 | . | 0.1099 | 5.42 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [A] 0.03% ZPT | 85 | 0.481 | -0.258 | 0.0015 | 0.0787 | 3.03 | -44.8 | -53.9 | -33.8 | 0.3284 |
|  | [B] 0.10% ZPT | 85 | 0.413 | -0.326 | <.0001 | 0.0787 | 2.59 | -52.7 | -60.6 | -43.4 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 0.724 | 0.000 | . | 0.1120 | 5.29 | 0.00 | 0.00 | 0.00 | 0.3727 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.654 | 0.000 | . | 0.1120 | 4.51 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [C] 0.03% ZPT | 84 | 0.357 | -0.340 | 0.0001 | 0.0841 | 2.27 | -54.3 | -62.3 | -44.5 | 0.6050 |
|  | [D] 0.03% ZPT + 0.06% ZC | 84 | 0.315 | -0.382 | <.0001 | 0.0841 | 2.06 | -58.5 | -65.8 | -49.6 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log IL1ra***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 2.101 | 0.000 | . | 0.0591 | 126.17 | 0.00 | 0.00 | 0.00 | 0.6488 |
|  | [B] 0.10% ZPT | 86 | 2.080 | 0.000 | . | 0.0591 | 120.20 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [A] 0.03% ZPT | 85 | 1.611 | -0.486 | <.0001 | 0.0486 | 40.81 | -67.3 | -70.8 | -63.4 | 0.1012 |
|  | [B] 0.10% ZPT | 85 | 1.693 | -0.404 | <.0001 | 0.0486 | 49.31 | -60.5 | -64.7 | -55.8 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 2.037 | 0.000 | . | 0.0654 | 108.89 | 0.00 | 0.00 | 0.00 | 0.2398 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 2.092 | 0.000 | . | 0.0654 | 123.56 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [C] 0.03% ZPT | 84 | 1.702 | -0.348 | <.0001 | 0.0543 | 50.39 | -55.1 | -60.4 | -49.2 | 0.1957 |
|  | [D] 0.03% ZPT + 0.06% ZC | 84 | 1.626 | -0.425 | <.0001 | 0.0543 | 42.23 | -62.4 | -66.8 | -57.4 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log IL1a***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 1.887 | 0.000 | . | 0.0398 | 77.16 | 0.00 | 0.00 | 0.00 | 0.7154 |
|  | [B] 0.10% ZPT | 86 | 1.878 | 0.000 | . | 0.0398 | 75.55 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [A] 0.03% ZPT | 85 | 1.619 | -0.259 | <.0001 | 0.0327 | 41.59 | -44.9 | -48.9 | -40.6 | 0.2916 |
|  | [B] 0.10% ZPT | 85 | 1.655 | -0.223 | <.0001 | 0.0327 | 45.19 | -40.1 | -44.5 | -35.5 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 1.837 | 0.000 | . | 0.0498 | 68.73 | 0.00 | 0.00 | 0.00 | 0.7537 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.846 | 0.000 | . | 0.0498 | 70.19 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [C] 0.03% ZPT | 84 | 1.656 | -0.191 | <.0001 | 0.0389 | 45.29 | -35.6 | -41.1 | -29.5 | 0.2965 |
|  | [D] 0.03% ZPT + 0.06% ZC | 84 | 1.616 | -0.231 | <.0001 | 0.0389 | 41.29 | -41.3 | -46.3 | -35.7 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Hsa Normalized***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 0.754 | 0.000 | . | 0.0768 | 5.67 | 0.00 | 0.00 | 0.00 | 0.6871 |
|  | [B] 0.10% ZPT | 86 | 0.733 | 0.000 | . | 0.0768 | 5.41 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [A] 0.03% ZPT | 85 | 0.253 | -0.497 | <.0001 | 0.0679 | 1.79 | -68.2 | -72.8 | -62.8 | 0.2577 |
|  | [B] 0.10% ZPT | 85 | 0.320 | -0.430 | <.0001 | 0.0679 | 2.09 | -62.9 | -68.3 | -56.6 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 0.738 | 0.000 | . | 0.0683 | 5.47 | 0.00 | 0.00 | 0.00 | 0.4100 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.695 | 0.000 | . | 0.0683 | 4.96 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [C] 0.03% ZPT | 84 | 0.310 | -0.391 | <.0001 | 0.0578 | 2.04 | -59.4 | -64.4 | -53.6 | 0.0323 |
|  | [D] 0.03% ZPT + 0.06% ZC | 84 | 0.453 | -0.248 | <.0001 | 0.0578 | 2.84 | -43.5 | -50.5 | -35.4 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Involucrin Normalized***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | -1.585 | 0.000 | . | 0.0370 | 0.03 | 0.00 | 0.00 | 0.00 | 0.1971 |
|  | [B] 0.10% ZPT | 86 | -1.540 | 0.000 | . | 0.0370 | 0.03 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [A] 0.03% ZPT | 85 | -1.678 | -0.114 | 0.0045 | 0.0390 | 0.02 | -23.1 | -29.7 | -15.8 | 0.0956 |
|  | [B] 0.10% ZPT | 85 | -1.614 | -0.050 | 0.2068 | 0.0390 | 0.02 | -10.8 | -18.4 | -2.41 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | -1.513 | 0.000 | . | 0.0427 | 0.03 | 0.00 | 0.00 | 0.00 | 0.2712 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | -1.555 | 0.000 | . | 0.0427 | 0.03 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [C] 0.03% ZPT | 84 | -1.605 | -0.057 | 0.1593 | 0.0404 | 0.02 | -12.4 | -20.2 | -3.84 | 0.4065 |
|  | [D] 0.03% ZPT + 0.06% ZC | 84 | -1.565 | -0.017 | 0.6777 | 0.0404 | 0.03 | -3.81 | -12.4 | 5.57 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Keratins11011 Normalized***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 0.722 | 0.000 | . | 0.0712 | 5.27 | 0.00 | 0.00 | 0.00 | 0.8236 |
|  | [B] 0.10% ZPT | 86 | 0.708 | 0.000 | . | 0.0712 | 5.11 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [A] 0.03% ZPT | 85 | 1.060 | 0.350 | <.0001 | 0.0426 | 11.47 | 123.8 | 102.9 | 146.8 | 0.4235 |
|  | [B] 0.10% ZPT | 85 | 1.024 | 0.314 | <.0001 | 0.0426 | 10.57 | 106.1 | 86.84 | 127.3 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 0.768 | 0.000 | . | 0.0594 | 5.86 | 0.00 | 0.00 | 0.00 | 0.5861 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.736 | 0.000 | . | 0.0594 | 5.44 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [C] 0.03% ZPT | 84 | 1.012 | 0.251 | <.0001 | 0.0360 | 10.29 | 78.22 | 64.05 | 93.62 | 0.5935 |
|  | [D] 0.03% ZPT + 0.06% ZC | 84 | 1.034 | 0.273 | <.0001 | 0.0360 | 10.82 | 87.52 | 72.61 | 103.7 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Protein SkinMap***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 1.148 | 0.000 | . | 0.0340 | 14.07 | 0.00 | 0.00 | 0.00 | 0.7299 |
|  | [B] 0.10% ZPT | 86 | 1.138 | 0.000 | . | 0.0340 | 13.73 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [A] 0.03% ZPT | 85 | 0.754 | -0.388 | <.0001 | 0.0403 | 5.68 | -59.1 | -62.7 | -55.1 | 0.1880 |
|  | [B] 0.10% ZPT | 85 | 0.812 | -0.331 | <.0001 | 0.0403 | 6.48 | -53.3 | -57.5 | -48.8 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 1.127 | 0.000 | . | 0.0381 | 13.41 | 0.00 | 0.00 | 0.00 | 0.7466 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.118 | 0.000 | . | 0.0381 | 13.11 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [C] 0.03% ZPT | 84 | 0.795 | -0.326 | <.0001 | 0.0420 | 6.24 | -52.7 | -57.1 | -47.9 | 0.2157 |
|  | [D] 0.03% ZPT + 0.06% ZC | 84 | 0.740 | -0.381 | <.0001 | 0.0420 | 5.49 | -58.4 | -62.2 | -54.1 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Hsa***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 1.902 | 0.000 | . | 0.0887 | 79.79 | 0.00 | 0.00 | 0.00 | 0.6195 |
|  | [B] 0.10% ZPT | 86 | 1.871 | 0.000 | . | 0.0887 | 74.25 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [A] 0.03% ZPT | 85 | 1.008 | -0.885 | <.0001 | 0.0789 | 10.18 | -87.0 | -89.1 | -84.4 | 0.0726 |
|  | [B] 0.10% ZPT | 85 | 1.130 | -0.762 | <.0001 | 0.0789 | 13.50 | -82.7 | -85.6 | -79.3 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 1.865 | 0.000 | . | 0.0862 | 73.29 | 0.00 | 0.00 | 0.00 | 0.3990 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.813 | 0.000 | . | 0.0862 | 64.97 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [C] 0.03% ZPT | 84 | 1.101 | -0.720 | <.0001 | 0.0728 | 12.62 | -81.0 | -83.9 | -77.5 | 0.1870 |
|  | [D] 0.03% ZPT + 0.06% ZC | 84 | 1.196 | -0.625 | <.0001 | 0.0728 | 15.72 | -76.3 | -79.9 | -71.9 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Involucrin***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | -0.437 | 0.000 | . | 0.0526 | 0.37 | 0.00 | 0.00 | 0.00 | 0.5035 |
|  | [B] 0.10% ZPT | 86 | -0.402 | 0.000 | . | 0.0526 | 0.40 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [A] 0.03% ZPT | 85 | -0.928 | -0.506 | <.0001 | 0.0475 | 0.12 | -68.8 | -72.1 | -65.2 | 0.0080 |
|  | [B] 0.10% ZPT | 85 | -0.798 | -0.377 | <.0001 | 0.0475 | 0.16 | -58.0 | -62.3 | -53.1 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | -0.386 | 0.000 | . | 0.0556 | 0.41 | 0.00 | 0.00 | 0.00 | 0.2586 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | -0.437 | 0.000 | . | 0.0556 | 0.37 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [C] 0.03% ZPT | 84 | -0.809 | -0.382 | <.0001 | 0.0514 | 0.16 | -58.5 | -63.1 | -53.3 | 0.7731 |
|  | [D] 0.03% ZPT + 0.06% ZC | 84 | -0.826 | -0.399 | <.0001 | 0.0514 | 0.15 | -60.1 | -64.5 | -55.0 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Keratins11011***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 1.870 | 0.000 | . | 0.0590 | 74.18 | 0.00 | 0.00 | 0.00 | 0.6185 |
|  | [B] 0.10% ZPT | 86 | 1.846 | 0.000 | . | 0.0590 | 70.17 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [A] 0.03% ZPT | 85 | 1.812 | -0.040 | 0.2027 | 0.0314 | 64.90 | -8.88 | -15.2 | -2.04 | 0.4625 |
|  | [B] 0.10% ZPT | 85 | 1.837 | -0.015 | 0.6316 | 0.0314 | 68.78 | -3.42 | -10.2 | 3.82 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 1.895 | 0.000 | . | 0.0504 | 78.53 | 0.00 | 0.00 | 0.00 | 0.3748 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.854 | 0.000 | . | 0.0504 | 71.38 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [C] 0.03% ZPT | 84 | 1.811 | -0.070 | 0.0406 | 0.0338 | 64.77 | -14.9 | -21.3 | -8.06 | 0.1437 |
|  | [D] 0.03% ZPT + 0.06% ZC | 84 | 1.770 | -0.112 | 0.0014 | 0.0338 | 58.85 | -22.7 | -28.5 | -16.5 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Malassezia***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 50 | 2.227 | 0.000 | . | 0.0464 | 168.62 | 0.00 | 0.00 | 0.00 | 0.8484 |
|  | [B] 0.10% ZPT | 50 | 2.235 | 0.000 | . | 0.0464 | 171.83 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [A] 0.03% ZPT | 50 | 1.098 | -1.133 | <.0001 | 0.0949 | 12.52 | -92.6 | -94.1 | -90.8 | 0.0001 |
|  | [B] 0.10% ZPT | 50 | 0.748 | -1.483 | <.0001 | 0.0949 | 5.59 | -96.7 | -97.4 | -95.9 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 50 | 2.252 | 0.000 | . | 0.0615 | 178.45 | 0.00 | 0.00 | 0.00 | 0.1924 |
|  | [D] 0.03% ZPT + 0.06% ZC | 50 | 2.202 | 0.000 | . | 0.0615 | 159.28 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [C] 0.03% ZPT | 49 | 1.289 | -0.938 | <.0001 | 0.1022 | 19.45 | -88.5 | -90.9 | -85.4 | 0.1396 |
|  | [D] 0.03% ZPT + 0.06% ZC | 49 | 1.173 | -1.054 | <.0001 | 0.1022 | 14.88 | -91.2 | -93.0 | -88.8 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Histamine Normalized***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | -0.574 | 0.000 | . | 0.1057 | 0.27 | 0.00 | 0.00 | 0.00 | 0.9208 |
|  | [B] 0.10% ZPT | 86 | -0.580 | 0.000 | . | 0.1057 | 0.26 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [A] 0.03% ZPT | 85 | -0.746 | -0.162 | 0.0375 | 0.0765 | 0.18 | -31.1 | -42.2 | -17.8 | 0.1173 |
|  | [B] 0.10% ZPT | 85 | -0.860 | -0.276 | 0.0005 | 0.0765 | 0.14 | -47.0 | -55.6 | -36.8 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | -0.598 | 0.000 | . | 0.1064 | 0.25 | 0.00 | 0.00 | 0.00 | 0.2364 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | -0.688 | 0.000 | . | 0.1064 | 0.21 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [C] 0.03% ZPT | 83 | -0.788 | -0.157 | 0.0787 | 0.0883 | 0.16 | -30.4 | -43.2 | -14.7 | 0.2610 |
|  | [D] 0.03% ZPT + 0.06% ZC | 83 | -0.868 | -0.237 | 0.0087 | 0.0883 | 0.14 | -42.1 | -52.8 | -29.1 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log IL1raIL1a Ratio***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 0.214 | 0.000 | . | 0.0681 | 1.64 | 0.00 | 0.00 | 0.00 | 0.7802 |
|  | [B] 0.10% ZPT | 86 | 0.202 | 0.000 | . | 0.0681 | 1.59 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [A] 0.03% ZPT | 85 | -0.083 | -0.286 | <.0001 | 0.0355 | 0.83 | -48.3 | -52.3 | -43.9 | 0.5241 |
|  | [B] 0.10% ZPT | 85 | -0.109 | -0.312 | <.0001 | 0.0355 | 0.78 | -51.3 | -55.1 | -47.1 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 0.200 | 0.000 | . | 0.0791 | 1.58 | 0.00 | 0.00 | 0.00 | 0.3189 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.246 | 0.000 | . | 0.0791 | 1.76 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [C] 0.03% ZPT | 83 | -0.024 | -0.241 | <.0001 | 0.0430 | 0.95 | -42.7 | -48.1 | -36.7 | 0.9188 |
|  | [D] 0.03% ZPT + 0.06% ZC | 83 | -0.029 | -0.246 | <.0001 | 0.0430 | 0.94 | -43.3 | -48.6 | -37.4 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log IL1ra Normalized***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 1.113 | 0.000 | . | 0.0434 | 12.98 | 0.00 | 0.00 | 0.00 | 0.5562 |
|  | [B] 0.10% ZPT | 86 | 1.094 | 0.000 | . | 0.0434 | 12.42 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [A] 0.03% ZPT | 85 | 0.815 | -0.288 | <.0001 | 0.0338 | 6.53 | -48.5 | -52.3 | -44.3 | 0.2855 |
|  | [B] 0.10% ZPT | 85 | 0.778 | -0.325 | <.0001 | 0.0338 | 5.99 | -52.7 | -56.3 | -48.9 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 1.084 | 0.000 | . | 0.0444 | 12.14 | 0.00 | 0.00 | 0.00 | 0.2957 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.118 | 0.000 | . | 0.0444 | 13.12 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [C] 0.03% ZPT | 83 | 0.829 | -0.270 | <.0001 | 0.0385 | 6.75 | -46.3 | -50.8 | -41.3 | 0.7446 |
|  | [D] 0.03% ZPT + 0.06% ZC | 83 | 0.818 | -0.281 | <.0001 | 0.0385 | 6.58 | -47.7 | -52.1 | -42.8 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log IL1a Normalized***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 0.900 | 0.000 | . | 0.0373 | 7.94 | 0.00 | 0.00 | 0.00 | 0.7491 |
|  | [B] 0.10% ZPT | 86 | 0.892 | 0.000 | . | 0.0373 | 7.81 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [A] 0.03% ZPT | 85 | 0.897 | -0.003 | 0.8982 | 0.0206 | 7.89 | -0.61 | -5.21 | 4.22 | 0.7020 |
|  | [B] 0.10% ZPT | 85 | 0.887 | -0.012 | 0.5459 | 0.0206 | 7.72 | -2.83 | -7.33 | 1.88 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 0.884 | 0.000 | . | 0.0463 | 7.66 | 0.00 | 0.00 | 0.00 | 0.6611 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.872 | 0.000 | . | 0.0463 | 7.45 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [C] 0.03% ZPT | 83 | 0.856 | -0.026 | 0.2883 | 0.0240 | 7.18 | -5.73 | -10.8 | -0.38 | 0.7021 |
|  | [D] 0.03% ZPT + 0.06% ZC | 83 | 0.844 | -0.037 | 0.1228 | 0.0240 | 6.99 | -8.24 | -13.2 | -3.04 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Protein Histamine***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 1.308 | 0.000 | . | 0.0238 | 20.31 | 0.00 | 0.00 | 0.00 | 0.7864 |
|  | [B] 0.10% ZPT | 86 | 1.314 | 0.000 | . | 0.0238 | 20.62 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [A] 0.03% ZPT | 85 | 1.135 | -0.176 | <.0001 | 0.0206 | 13.64 | -33.3 | -36.3 | -30.0 | 0.2350 |
|  | [B] 0.10% ZPT | 85 | 1.111 | -0.199 | <.0001 | 0.0206 | 12.92 | -36.8 | -39.7 | -33.7 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 1.321 | 0.000 | . | 0.0264 | 20.96 | 0.00 | 0.00 | 0.00 | 0.3804 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.342 | 0.000 | . | 0.0264 | 21.97 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [C] 0.03% ZPT | 83 | 1.134 | -0.194 | <.0001 | 0.0235 | 13.61 | -36.0 | -39.4 | -32.4 | 0.6704 |
|  | [D] 0.03% ZPT + 0.06% ZC | 83 | 1.143 | -0.185 | <.0001 | 0.0235 | 13.89 | -34.7 | -38.1 | -31.1 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Protein Cytokine***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 0.988 | 0.000 | . | 0.0294 | 9.72 | 0.00 | 0.00 | 0.00 | 0.9484 |
|  | [B] 0.10% ZPT | 86 | 0.986 | 0.000 | . | 0.0294 | 9.68 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [A] 0.03% ZPT | 85 | 0.734 | -0.253 | <.0001 | 0.0300 | 5.42 | -44.1 | -47.9 | -40.1 | 0.1699 |
|  | [B] 0.10% ZPT | 85 | 0.693 | -0.294 | <.0001 | 0.0300 | 4.93 | -49.2 | -52.6 | -45.6 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 0.953 | 0.000 | . | 0.0354 | 8.97 | 0.00 | 0.00 | 0.00 | 0.4492 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.974 | 0.000 | . | 0.0354 | 9.42 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [C] 0.03% ZPT | 83 | 0.725 | -0.234 | <.0001 | 0.0297 | 5.31 | -41.7 | -45.5 | -37.5 | 0.4744 |
|  | [D] 0.03% ZPT + 0.06% ZC | 83 | 0.706 | -0.253 | <.0001 | 0.0297 | 5.08 | -44.2 | -47.9 | -40.2 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Histamine***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 0.734 | 0.000 | . | 0.1099 | 5.42 | 0.00 | 0.00 | 0.00 | 0.9990 |
|  | [B] 0.10% ZPT | 86 | 0.734 | 0.000 | . | 0.1099 | 5.42 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [A] 0.03% ZPT | 85 | 0.390 | -0.336 | 0.0001 | 0.0829 | 2.45 | -53.9 | -61.9 | -44.2 | 0.0562 |
|  | [B] 0.10% ZPT | 85 | 0.250 | -0.476 | <.0001 | 0.0829 | 1.78 | -66.6 | -72.4 | -59.5 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 0.724 | 0.000 | . | 0.1120 | 5.29 | 0.00 | 0.00 | 0.00 | 0.3727 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.654 | 0.000 | . | 0.1120 | 4.51 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [C] 0.03% ZPT | 83 | 0.351 | -0.346 | 0.0008 | 0.0990 | 2.24 | -54.9 | -64.1 | -43.4 | 0.2576 |
|  | [D] 0.03% ZPT + 0.06% ZC | 83 | 0.270 | -0.427 | <.0001 | 0.0990 | 1.86 | -62.6 | -70.2 | -53.0 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log IL1ra***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 2.101 | 0.000 | . | 0.0591 | 126.17 | 0.00 | 0.00 | 0.00 | 0.6488 |
|  | [B] 0.10% ZPT | 86 | 2.080 | 0.000 | . | 0.0591 | 120.20 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [A] 0.03% ZPT | 85 | 1.550 | -0.540 | <.0001 | 0.0522 | 35.46 | -71.2 | -74.4 | -67.5 | 0.1094 |
|  | [B] 0.10% ZPT | 85 | 1.469 | -0.621 | <.0001 | 0.0522 | 29.46 | -76.0 | -78.8 | -73.0 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 2.037 | 0.000 | . | 0.0654 | 108.89 | 0.00 | 0.00 | 0.00 | 0.2398 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 2.092 | 0.000 | . | 0.0654 | 123.56 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [C] 0.03% ZPT | 83 | 1.554 | -0.504 | <.0001 | 0.0597 | 35.81 | -68.7 | -72.7 | -64.1 | 0.5728 |
|  | [D] 0.03% ZPT + 0.06% ZC | 83 | 1.524 | -0.534 | <.0001 | 0.0597 | 33.46 | -70.7 | -74.5 | -66.4 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log IL1a***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 1.887 | 0.000 | . | 0.0398 | 77.16 | 0.00 | 0.00 | 0.00 | 0.7154 |
|  | [B] 0.10% ZPT | 86 | 1.878 | 0.000 | . | 0.0398 | 75.55 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [A] 0.03% ZPT | 85 | 1.631 | -0.256 | <.0001 | 0.0358 | 42.76 | -44.5 | -48.9 | -39.7 | 0.1303 |
|  | [B] 0.10% ZPT | 85 | 1.580 | -0.307 | <.0001 | 0.0358 | 38.02 | -50.6 | -54.5 | -46.4 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 1.837 | 0.000 | . | 0.0498 | 68.73 | 0.00 | 0.00 | 0.00 | 0.7537 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.846 | 0.000 | . | 0.0498 | 70.19 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [C] 0.03% ZPT | 83 | 1.583 | -0.257 | <.0001 | 0.0392 | 38.32 | -44.7 | -49.5 | -39.5 | 0.3329 |
|  | [D] 0.03% ZPT + 0.06% ZC | 83 | 1.548 | -0.293 | <.0001 | 0.0392 | 35.29 | -49.1 | -53.5 | -44.3 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Hsa Normalized***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 0.754 | 0.000 | . | 0.0768 | 5.67 | 0.00 | 0.00 | 0.00 | 0.6871 |
|  | [B] 0.10% ZPT | 86 | 0.733 | 0.000 | . | 0.0768 | 5.41 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [A] 0.03% ZPT | 85 | 0.163 | -0.572 | <.0001 | 0.0601 | 1.46 | -73.2 | -76.7 | -69.2 | 0.5152 |
|  | [B] 0.10% ZPT | 85 | 0.121 | -0.614 | <.0001 | 0.0601 | 1.32 | -75.7 | -78.8 | -72.1 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 0.738 | 0.000 | . | 0.0683 | 5.47 | 0.00 | 0.00 | 0.00 | 0.4100 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.695 | 0.000 | . | 0.0683 | 4.96 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [C] 0.03% ZPT | 83 | 0.214 | -0.495 | <.0001 | 0.0654 | 1.64 | -68.0 | -72.5 | -62.8 | 0.3341 |
|  | [D] 0.03% ZPT + 0.06% ZC | 83 | 0.286 | -0.422 | <.0001 | 0.0654 | 1.93 | -62.2 | -67.5 | -56.0 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Involucrin Normalized***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | -1.585 | 0.000 | . | 0.0370 | 0.03 | 0.00 | 0.00 | 0.00 | 0.1971 |
|  | [B] 0.10% ZPT | 86 | -1.540 | 0.000 | . | 0.0370 | 0.03 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [A] 0.03% ZPT | 85 | -1.626 | -0.062 | 0.1133 | 0.0386 | 0.02 | -13.2 | -20.6 | -5.19 | 0.0779 |
|  | [B] 0.10% ZPT | 85 | -1.711 | -0.147 | 0.0003 | 0.0386 | 0.02 | -28.7 | -34.8 | -22.1 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | -1.513 | 0.000 | . | 0.0427 | 0.03 | 0.00 | 0.00 | 0.00 | 0.2712 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | -1.555 | 0.000 | . | 0.0427 | 0.03 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [C] 0.03% ZPT | 83 | -1.614 | -0.074 | 0.0718 | 0.0406 | 0.02 | -15.7 | -23.2 | -7.42 | 0.6814 |
|  | [D] 0.03% ZPT + 0.06% ZC | 83 | -1.593 | -0.053 | 0.1945 | 0.0406 | 0.03 | -11.5 | -19.4 | -2.84 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Keratins11011 Normalized***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 0.722 | 0.000 | . | 0.0712 | 5.27 | 0.00 | 0.00 | 0.00 | 0.8236 |
|  | [B] 0.10% ZPT | 86 | 0.708 | 0.000 | . | 0.0712 | 5.11 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [A] 0.03% ZPT | 85 | 1.042 | 0.332 | <.0001 | 0.0480 | 11.02 | 114.9 | 92.41 | 140.0 | 0.3389 |
|  | [B] 0.10% ZPT | 85 | 1.099 | 0.389 | <.0001 | 0.0480 | 12.56 | 145.0 | 119.4 | 173.6 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 0.768 | 0.000 | . | 0.0594 | 5.86 | 0.00 | 0.00 | 0.00 | 0.5861 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.736 | 0.000 | . | 0.0594 | 5.44 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [C] 0.03% ZPT | 83 | 0.988 | 0.232 | <.0001 | 0.0465 | 9.72 | 70.47 | 53.17 | 89.72 | 0.7386 |
|  | [D] 0.03% ZPT + 0.06% ZC | 83 | 0.971 | 0.215 | <.0001 | 0.0465 | 9.36 | 64.22 | 47.56 | 82.76 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Protein SkinMap***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 1.148 | 0.000 | . | 0.0340 | 14.07 | 0.00 | 0.00 | 0.00 | 0.7299 |
|  | [B] 0.10% ZPT | 86 | 1.138 | 0.000 | . | 0.0340 | 13.73 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [A] 0.03% ZPT | 85 | 0.774 | -0.370 | <.0001 | 0.0410 | 5.94 | -57.4 | -61.2 | -53.2 | 0.9183 |
|  | [B] 0.10% ZPT | 85 | 0.769 | -0.375 | <.0001 | 0.0410 | 5.87 | -57.8 | -61.6 | -53.7 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 1.127 | 0.000 | . | 0.0381 | 13.41 | 0.00 | 0.00 | 0.00 | 0.7466 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.118 | 0.000 | . | 0.0381 | 13.11 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [C] 0.03% ZPT | 83 | 0.764 | -0.356 | <.0001 | 0.0454 | 5.81 | -55.9 | -60.3 | -51.1 | 0.6046 |
|  | [D] 0.03% ZPT + 0.06% ZC | 83 | 0.786 | -0.334 | <.0001 | 0.0454 | 6.12 | -53.6 | -58.2 | -48.5 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Hsa***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 1.902 | 0.000 | . | 0.0887 | 79.79 | 0.00 | 0.00 | 0.00 | 0.6195 |
|  | [B] 0.10% ZPT | 86 | 1.871 | 0.000 | . | 0.0887 | 74.25 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [A] 0.03% ZPT | 85 | 0.938 | -0.941 | <.0001 | 0.0719 | 8.67 | -88.6 | -90.3 | -86.5 | 0.5248 |
|  | [B] 0.10% ZPT | 85 | 0.889 | -0.990 | <.0001 | 0.0719 | 7.74 | -89.8 | -91.3 | -87.9 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 1.865 | 0.000 | . | 0.0862 | 73.29 | 0.00 | 0.00 | 0.00 | 0.3990 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.813 | 0.000 | . | 0.0862 | 64.97 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [C] 0.03% ZPT | 83 | 0.979 | -0.850 | <.0001 | 0.0817 | 9.52 | -85.9 | -88.3 | -82.9 | 0.2505 |
|  | [D] 0.03% ZPT + 0.06% ZC | 83 | 1.071 | -0.757 | <.0001 | 0.0817 | 11.79 | -82.5 | -85.5 | -78.9 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Involucrin***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | -0.437 | 0.000 | . | 0.0526 | 0.37 | 0.00 | 0.00 | 0.00 | 0.5035 |
|  | [B] 0.10% ZPT | 86 | -0.402 | 0.000 | . | 0.0526 | 0.40 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [A] 0.03% ZPT | 85 | -0.856 | -0.436 | <.0001 | 0.0461 | 0.14 | -63.4 | -67.1 | -59.3 | 0.1220 |
|  | [B] 0.10% ZPT | 85 | -0.938 | -0.518 | <.0001 | 0.0461 | 0.12 | -69.7 | -72.7 | -66.3 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | -0.386 | 0.000 | . | 0.0556 | 0.41 | 0.00 | 0.00 | 0.00 | 0.2586 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | -0.437 | 0.000 | . | 0.0556 | 0.37 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [C] 0.03% ZPT | 83 | -0.848 | -0.428 | <.0001 | 0.0518 | 0.14 | -62.7 | -66.9 | -58.0 | 0.4691 |
|  | [D] 0.03% ZPT + 0.06% ZC | 83 | -0.809 | -0.388 | <.0001 | 0.0518 | 0.16 | -59.1 | -63.7 | -53.9 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Keratins11011***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 1.870 | 0.000 | . | 0.0590 | 74.18 | 0.00 | 0.00 | 0.00 | 0.6185 |
|  | [B] 0.10% ZPT | 86 | 1.846 | 0.000 | . | 0.0590 | 70.17 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [A] 0.03% ZPT | 85 | 1.815 | -0.039 | 0.2748 | 0.0354 | 65.33 | -8.57 | -15.7 | -0.81 | 0.2142 |
|  | [B] 0.10% ZPT | 85 | 1.869 | 0.015 | 0.6790 | 0.0354 | 73.91 | 3.44 | -4.65 | 12.22 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 1.895 | 0.000 | . | 0.0504 | 78.53 | 0.00 | 0.00 | 0.00 | 0.3748 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.854 | 0.000 | . | 0.0504 | 71.38 | 0.00 | 0.00 | 0.00 | . |
| Week 3 | [C] 0.03% ZPT | 83 | 1.749 | -0.126 | 0.0012 | 0.0377 | 56.17 | -25.3 | -31.5 | -18.5 | 0.7743 |
|  | [D] 0.03% ZPT + 0.06% ZC | 83 | 1.760 | -0.116 | 0.0029 | 0.0377 | 57.56 | -23.4 | -29.8 | -16.5 | . |
|  | | | | | | | | | | | |